Most people with less common forms of Alzheimer's disease would not qualify for the anti-amyloid drugs designed to slow it, according to research published August 5 in Neurology. Among 184 people with biomarker-confirmed atypical Alzheimer's disease, between 70 and 85 percent would not meet the eligibility criteria for lecanemab or donanemab, the study found. "Atypical Alzheimer's disease is often underrecognized and underrepresented in clinical trials," said study author Dror Shir of the Mayo Clinic in Jacksonville, Florida. It did not test whether the drugs work in atypical Alzheimer's, and it produced no evidence on that question either way. Between 70 and 85 percent of 184 people with biomarker-confirmed atypical Alzheimer's would not meet lecanemab or donanemab eligibility criteria.